Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLS-009
- Development stage
- Preclinical
- Lead developer
- SELLAS Life Sciences Group
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
SLS-009 is a preclinical-stage therapeutic program developed by Seelos Therapeutics that utilizes proteolysis-targeting chimera (PROTAC) technology. It is designed to selectively degrade disease-causing proteins by harnessing the body's natural autophagy and lysosomal degradation pathways, rather than the more common ubiquitin-proteasome system. The program aims to clear mutant and misfolded protein aggregates associated with neurodegenerative conditions. Currently, SLS-009 is being evaluated in preclinical in vivo studies for the treatment of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Huntington's disease.
02
Targets
mHTT (Mutant Huntingtin Protein)CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)
Beyond the preview
Go deeper on SLS-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLS-009.